+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: A comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector



Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: A comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector



Vaccine 20(5-6): 961-971



The humoral and cytotoxic T-lymphocyte (CTL) responses have been shown to be determinant in the clearance of many viral infections and because of those characteristics, vaccine candidates against AIDS are designed to enhance both arms of the immune system. While a protocol of immunization able to confer protection in humans against HIV will have to await the results of current clinical trials, it remains important to identify protocols of immunization in animals that achieve significant levels of humoral and cellular immune responses to HIV. In this study we have carried out a comparative analysis of the immune responses elicited in mice immunized with recombinants based on the modified vaccinia virus Ankara strain (rMVA) versus the Western Reserve strain (WR) of vaccinia virus (rVV), both expressing a V3 loop multi-epitopic protein from eight different HIV isolates (TAB13). We found that during priming, rMVA elicited a two- to three-fold higher specific CD8+ T cell response than rVV. Similar enhancement was observed during priming with purified protein TAB13 followed by a booster with rMVA. The epitopes LR150, MN and IIIB, located at the ends and in the middle of the chimeric protein, were able to induce a specific CD8+ T cell response, both after priming or prime/booster with the recombinant viruses but not after prime/booster with TAB13. By examining the cytokine pattern, the immune response triggered by these vectors was of Th-1 type. Humoral immune responses were higher in animals immunized with TAB13/TAB13 or TAB13/rVV than in animals immunized with TAB13/rMVA. These findings demonstrate that during priming or in a prime/booster immunizations, rMVA is superior to rVV in the ability to enhance specific cellular responses to an HIV-1 protein, and that both humoral and cellular immune responses to the V3 loop epitope of HIV-1 Env can be obtained by priming with TAB13 followed by a booster with viral vectors.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010588676

Download citation: RISBibTeXText

PMID: 11738764

DOI: 10.1016/s0264-410x(01)00389-9


Related references

Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara recombinant A comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve vector. Vaccine 20(5-6): 961-971, 12 December, 2001

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. Journal of Virology 74(2): 923-933, 2000

Co-expressing GP5 and M proteins under different promoters in recombinant modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV). Virus Genes 35(3): 585-595, 2007

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees. Aids Research and Human Retroviruses 30(3): 299-311, 2014

Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus. Clinical and Diagnostic Laboratory Immunology 11(2): 406-410, 2004

Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki forest virus and boosting with modified vaccinia virus Ankara. Vaccine 19(25-26): 3526-3536, 2001

Modified-vaccinia-virus-Ankara (MVA) priming and fowlpox-virus booster elicit a stronger CD8+ T-cell response in mice against an HIV-1 epitope than does a DNA/poxvirus prime-booster approach. Biotechnology and Applied Biochemistry 39(Pt 3): 313-318, 2004

Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins. Vaccines 5(4):, 2017

Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses. Journal of Virology 88(24): 14396-14411, 2014

Modified-vaccinia-virus-ankara (MVA) priming and fowlpoxvirus booster elicit a stronger CD8+ T-cell response in mice against an HIV-I than does a DNA/poxvirus prime-booster approach. Biotechnology and Applied Biochemistry 39(Part 3): 313-318, 2004

Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses. Journal of Virology 80(15): 7676-7687, 2006

Different contribution of co-stimulatory molecules B7.1 and B7.2 to the immune response to recombinant modified vaccinia virus ankara vaccine expressing prM/E proteins of Japanese encephalitis virus and two hepatitis B virus vaccines. Acta Virologica 51(2): 125-130, 2007

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 19(32): 4595-4602, 2001

Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice. Journal of Virology 92(19):, 2018

Hepatitis C virus-specific cellular and humoral immune responses following immunization with a multi-epitope fusion protein. International Journal of Molecular Medicine 29(1): 12-17, 2012